Gilteritinib plus CUDC-907 – A Novel Therapeutic Combination with The Ability to Overcome Drug Resistance
In this study, we showed that combining the second-generation FLT3 inhibitor gilteritinib with the dual PI3K/HDAC inhibitor CUDC-907 synergistically improved anti-leukemic activity against FLT3-ITD acute myeloid leukemia (AML) – and that each agent reciprocally overcame resistance to the other drug.